Polman CH - Search Results

1

Multiple sclerosis therapy. A practical guide.

van Oosten BW, Truyen L, Barkhof F, Polman CH. van Oosten BW, et al. Among authors: polman ch. Drugs. 1995 Feb;49(2):200-12. doi: 10.2165/00003495-199549020-00005. Drugs. 1995. PMID: 7729328 Review.

2

Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.

van Walderveen MA, Truyen L, van Oosten BW, Castelijns JA, Lycklama à Nijeholt GJ, van Waesberghe JH, Polman C, Barkhof F. van Walderveen MA, et al. Arch Neurol. 1999 Mar;56(3):345-51. doi: 10.1001/archneur.56.3.345. Arch Neurol. 1999. PMID: 10190826

3

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Adèr HJ, Barkhof F. Truyen L, et al. Among authors: polman ch. Neurology. 1996 Dec;47(6):1469-76. doi: 10.1212/wnl.47.6.1469. Neurology. 1996. PMID: 8960729

4

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. van Oosten BW, et al. Among authors: polman ch. Neurology. 1996 Dec;47(6):1531-4. doi: 10.1212/wnl.47.6.1531. Neurology. 1996. PMID: 8960740

5

Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions.

van Waesberghe JH, Castelijns JA, Scheltens P, Truyen L, Lycklana A Nijeholt GJ, Hoogenraad FG, Polman CH, Valk J, Barkhof F. van Waesberghe JH, et al. Among authors: polman ch. Magn Reson Imaging. 1997;15(2):155-62. doi: 10.1016/s0730-725x(96)00340-2. Magn Reson Imaging. 1997. PMID: 9106143 Clinical Trial.

6

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.

van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH. van Oosten BW, et al. Among authors: polman ch. Neurology. 1997 Aug;49(2):351-7. doi: 10.1212/wnl.49.2.351. Neurology. 1997. PMID: 9270561 Clinical Trial.

7

Interleukin-2 therapy does not exacerbate multiple sclerosis.

van Oosten BW, Uitdehaag BM, Barkhof F, Hartung HP, Wagstaff J, Polman CH. van Oosten BW, et al. Among authors: polman ch. Neurology. 1997 Aug;49(2):633-4. doi: 10.1212/wnl.49.2.633. Neurology. 1997. PMID: 9270618 No abstract available.

8

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

van Oosten BW, Lai M, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Hodgkinson S, Polman CH. van Oosten BW, et al. Among authors: polman ch. Mult Scler. 1996 Jul;1(6):339-42. doi: 10.1177/135245859600100611. Mult Scler. 1996. PMID: 9345413 Clinical Trial.

9

Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine.

Truyen L, Barkhof F, Frequin ST, Polman CH, Tobi H, Hommes OR, Valk J. Truyen L, et al. Among authors: polman ch. Mult Scler. 1996 Feb;1(4):213-7. Mult Scler. 1996. PMID: 9345437

10

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

van Oosten BW, Barkhof F, Scholten PE, von Blomberg BM, Adèr HJ, Polman CH. van Oosten BW, et al. Among authors: polman ch. Arch Neurol. 1998 Jun;55(6):793-8. doi: 10.1001/archneur.55.6.793. Arch Neurol. 1998. PMID: 9626770

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

470 results

Search Page

Filters